253
Participants
Start Date
November 20, 2006
Primary Completion Date
October 5, 2008
Study Completion Date
November 3, 2008
Preladenant
1 mg BID capsules
Preladenant
2 mg BID capsules
Preladenant
5 mg BID capsules
Preladenant
10 mg BID capsules
Placebo
BID capsules
L-dopa
Participants must receive L-dopa as part of their usual ongoing treatment for Parkinson's Disease. L-dopa is often administered concomitantly with a dopa decarboxylase inhibitor (e.g., carbidopa).
Other Parkinson's Disease treatments
Participants may also receive other drugs as part of their usual ongoing treatment for Parkinson's Disease, such as dopamine agonists (e.g., pramipexole) and/or the catechol-O-methyl transferase (COMT) inhibitor entacapone.
Merck Sharp & Dohme LLC
INDUSTRY